Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 5/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.37 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492925 | 0.91 | SLC16A3 (0.39) | CCKARSLC16A3SLC16A1MCTS1BRS3 | |
| SCHEMBL3494697 | 0.83 | CA1 (0.44) | SMN1; SMN2ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL5134025 | 0.83 | CA1 (0.44) | SMN1; SMN2ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL3493296 | 0.83 | CA1 (0.39) | SMN1; SMN2KIF11CA1CA2CA4 | |
| SCHEMBL5133998 | 0.83 | CA1 (0.39) | SMN1; SMN2KIF11CA1CA2CA4 | |
| SCHEMBL3495525 | 0.82 | SLC16A3 (0.35) | SLC16A3SLC16A1MCTS1BRS3CDC7 | |
| SCHEMBL3495488 | 0.82 | SLC16A3 (0.35) | SLC16A3SLC16A1MCTS1BRS3CDC7 | |
| SCHEMBL3495801 | 0.82 | JMJD6 (0.41) | SMN1; SMN2KDM4EALDH1A1CA1CA2 | |
| SCHEMBL3495798 | 0.81 | CA1 (0.36) | SLC16A3SLC16A1MCTS1BRS3SMN1; SMN2 | |
| SCHEMBL13341007 | 0.80 | CA1 (0.42) | SMN1; SMN2KDM4EALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CCKAR 150/4885SLC16A3 3861/4885SLC16A1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.